{
    "hands_on_practices": [
        {
            "introduction": "Understanding the inheritance of HLA haplotypes is fundamental to transplantation medicine. While we often learn the simplified probability that two siblings are a perfect match is $1/4$, the reality is slightly more complex due to meiotic recombination within the MHC region. This practice challenges you to derive the probability of a full HLA match from first principles, incorporating the recombination fraction $r$ to develop a more accurate and realistic genetic model .",
            "id": "5055655",
            "problem": "A couple is being evaluated for sibling Human Leukocyte Antigen (HLA) matching across the classical loci HLA-A, HLA-B, and HLA-DRB1, which reside within the Major Histocompatibility Complex (MHC) on chromosome $6$. Each parent carries two distinct HLA haplotypes defined across these typed loci: the father has haplotypes $H_1$ and $H_2$, and the mother has haplotypes $H_3$ and $H_4$, with $H_1$, $H_2$, $H_3$, and $H_4$ all mutually different at the typed loci.\n\nUse the following foundational principles:\n- Mendelian segregation: each child independently receives one haplotype from the father and one from the mother, with probability $1/2$ for each haplotype per parent.\n- Meiotic recombination: treat the three typed loci together as a single haplotype block with an overall recombination fraction $r$ per meiosis such that a gamete is nonrecombinant with probability $(1-r)$ and recombinant with probability $r$. Assume independent meioses for different conceptions and for the two parents.\n- High polymorphism and locus density: assume that if recombination occurs within this block, the resulting recombinant haplotype differs from the nonrecombinant parental haplotypes and that the probability two independent recombinations produce identical recombinant haplotypes across all typed loci is negligible.\n\nUnder these assumptions, derive from first principles the probability that two independently conceived full siblings are fully HLA-identical across HLA-A, HLA-B, and HLA-DRB1. Then, using $r = 0.02$, compute the numerical value of this probability and express the final result as a decimal fraction. Round your answer to four significant figures.",
            "solution": "The user wants me to solve a problem in medical genetics.\n\nHere's my plan:\n1.  **Validate the problem statement.**\n    *   **Step 1: Extract Givens:** I will list all the information provided in the problem.\n        *   Parents: Father and Mother.\n        *   Loci: HLA-A, HLA-B, and HLA-DRB1 on chromosome $6$.\n        *   Father's haplotypes: $H_1$ and $H_2$. They are distinct.\n        *   Mother's haplotypes: $H_3$ and $H_4$. They are distinct.\n        *   All four parental haplotypes ($H_1, H_2, H_3, H_4$) are mutually different.\n        *   Mendelian segregation: A child receives one haplotype from each parent, each with probability $1/2$. This principle is further refined by the recombination model.\n        *   Meiotic recombination: The three loci are treated as a single haplotype block.\n        *   Recombination fraction: $r$ per meiosis.\n        *   Probability of a nonrecombinant gamete: $1-r$.\n        *   Probability of a recombinant gamete: $r$.\n        *   Independent meioses for different conceptions and for the two parents.\n        *   Assumption about recombination: If recombination occurs, the resulting haplotype differs from the nonrecombinant parental haplotypes. The probability that two independent recombinations produce identical recombinant haplotypes is negligible.\n        *   Goal: Derive the probability that two full siblings are fully HLA-identical across the three loci.\n        *   Numerical value: Calculate this probability for $r = 0.02$.\n        *   Final format: Decimal fraction rounded to four significant figures.\n\n    *   **Step 2: Validate Using Extracted Givens:**\n        *   **Scientifically Grounded?** Yes. The problem is based on fundamental principles of Mendelian genetics, including segregation, independent assortment (between parents), and meiotic recombination. The context of HLA genetics is appropriate and common for such problems. The specified loci are standard in clinical HLA typing.\n        *   **Well-Posed?** Yes. All necessary parameters ($r$, parental haplotypes) and simplifying assumptions (uniqueness of recombinants, independent meioses) are provided. The objective is clearly stated. A unique probabilistic solution exists.\n        *   **Objective?** Yes. The language is formal and precise, typical of a scientific problem statement. It is free from subjectivity.\n        *   **Invalidity Checklist:**\n            1.  **Scientific or Factual Unsoundness:** None. The model is a standard, albeit simplified, representation of genetic inheritance.\n            2.  **Non-Formalizable or Irrelevant:** None. The problem is directly formalizable using probability theory and is relevant to medical genetics.\n            3.  **Incomplete or Contradictory Setup:** None. The problem is self-contained and internally consistent.\n            4.  **Unrealistic or Infeasible:** None. The value of $r=0.02$ is a plausible recombination frequency for the MHC region. The assumptions are standard for introductory genetics problems.\n            5.  **Ill-Posed or Poorly Structured:** None. The question is unambiguous.\n            6.  **Pseudo-Profound, Trivial, or Tautological:** None. The problem requires a careful application of probability rules in a non-trivial context (i.e., including recombination).\n            7.  **Outside Scientific Verifiability:** None. The result is verifiable within the given mathematical model.\n\n    *   **Step 3: Verdict and Action:** The problem is deemed **valid**. I will proceed with the full solution.\n\n2.  **Solve the problem.**\n    The problem asks for the probability that two independently conceived full siblings are fully HLA-identical. This means they must have the same pair of HLA haplotypes.\n\n    Let the father's genotype be represented as the pair of haplotypes $(H_1, H_2)$ and the mother's as $(H_3, H_4)$. The problem states that $H_1, H_2, H_3, H_4$ are all distinct.\n\n    A child's genotype is formed by inheriting one haplotype from the father and one from the mother. The process of gamete formation in each parent is subject to meiotic recombination with a recombination fraction $r$.\n\n    First, let's determine the probabilities of different types of gametes produced by a single parent, for instance, the father with genotype $(H_1, H_2)$. According to the problem statement, a gamete is nonrecombinant with probability $(1-r)$ and recombinant with probability $r$. In a large pool of gametes from this parent, the haplotypes $H_1$ and $H_2$ are expected to be present in equal proportions. Therefore, a gamete will contain a nonrecombinant haplotype $H_1$ with probability $\\frac{1-r}{2}$ and a nonrecombinant haplotype $H_2$ with probability $\\frac{1-r}{2}$. The remaining probability, $r$, corresponds to the formation of recombinant haplotypes. Let's denote a recombinant haplotype from the father as $R_F$.\n\n    So, for a child, the probability of inheriting a specific haplotype from the father is:\n    -   $P(\\text{inherits } H_1) = \\frac{1-r}{2}$\n    -   $P(\\text{inherits } H_2) = \\frac{1-r}{2}$\n    -   $P(\\text{inherits any recombinant } R_F) = r$\n\n    Similarly, for the mother with genotype $(H_3, H_4)$, the probabilities are:\n    -   $P(\\text{inherits } H_3) = \\frac{1-r}{2}$\n    -   $P(\\text{inherits } H_4) = \\frac{1-r}{2}$\n    -   $P(\\text{inherits any recombinant } R_M) = r$\n\n    Let Sibling 1 ($S_1$) and Sibling 2 ($S_2$) be two independently conceived children. Let their genotypes be $G_1 = (H_{p1}, H_{m1})$ and $G_2 = (H_{p2}, H_{m2})$, where $H_{pi}$ is the haplotype inherited from the father and $H_{mi}$ is the haplotype inherited from the mother for sibling $i \\in \\{1, 2\\}$.\n\n    The siblings are fully HLA-identical if their genotypes are identical, i.e., $G_1 = G_2$. Since the parental haplotypes are all distinct ($H_1, H_2, H_3, H_4$), and recombinant haplotypes are assumed to be unique and distinct from parental ones, a paternal haplotype can never be identical to a maternal haplotype. Therefore, for the genotypes to be identical, the siblings must have inherited the same haplotype from the father AND the same haplotype from the mother. That is, $G_1=G_2$ if and only if $H_{p1} = H_{p2}$ and $H_{m1} = H_{m2}$.\n\n    The inheritances from the father and mother are independent events. Thus, the probability of the siblings being identical is:\n    $P(G_1 = G_2) = P(H_{p1} = H_{p2} \\text{ and } H_{m1} = H_{m2})$\n    $P(G_1 = G_2) = P(H_{p1} = H_{p2}) \\times P(H_{m1} = H_{m2})$\n\n    Let's calculate the probability that both siblings inherit the same haplotype from the father, $P(H_{p1} = H_{p2})$. This can occur if both inherit $H_1$, or both inherit $H_2$, or both inherit the *same* recombinant haplotype.\n    -   The probability that both inherit $H_1$ is $P(H_{p1}=H_1) \\times P(H_{p2}=H_1) = \\left(\\frac{1-r}{2}\\right) \\times \\left(\\frac{1-r}{2}\\right) = \\frac{(1-r)^2}{4}$.\n    -   The probability that both inherit $H_2$ is $P(H_{p1}=H_2) \\times P(H_{p2}=H_2) = \\left(\\frac{1-r}{2}\\right) \\times \\left(\\frac{1-r}{2}\\right) = \\frac{(1-r)^2}{4}$.\n    -   The probability that both inherit a recombinant haplotype is $P(H_{p1} \\text{ is recombinant and } H_{p2} \\text{ is recombinant}) = r \\times r = r^2$. However, the problem explicitly states that \"the probability two independent recombinations produce identical recombinant haplotypes...is negligible.\" This means that even if both siblings inherit a recombinant haplotype, the probability that these two haplotypes are identical is $0$. Therefore, this path does not contribute to the siblings being identical.\n\n    The total probability of inheriting the same haplotype from the father is the sum of the probabilities for the mutually exclusive events of inheriting $H_1$ or $H_2$:\n    $P(H_{p1} = H_{p2}) = \\frac{(1-r)^2}{4} + \\frac{(1-r)^2}{4} = 2 \\times \\frac{(1-r)^2}{4} = \\frac{(1-r)^2}{2}$.\n\n    The inheritance process for the mother is identical. Therefore, the probability that both siblings inherit the same haplotype from the mother is also:\n    $P(H_{m1} = H_{m2}) = \\frac{(1-r)^2}{2}$.\n\n    Now, we can find the total probability that the two siblings are fully HLA-identical:\n    $P(\\text{identical}) = P(H_{p1} = H_{p2}) \\times P(H_{m1} = H_{m2}) = \\left(\\frac{(1-r)^2}{2}\\right) \\times \\left(\\frac{(1-r)^2}{2}\\right) = \\frac{(1-r)^4}{4}$.\n\n    This is the general formula derived from first principles. As a check, for the case of no recombination ($r=0$), the probability becomes $\\frac{(1-0)^4}{4} = \\frac{1}{4}$, which is the classic Mendelian probability for fully matched siblings.\n\n    Now, we must compute the numerical value for $r = 0.02$.\n    $P(\\text{identical}) = \\frac{(1 - 0.02)^4}{4} = \\frac{(0.98)^4}{4}$.\n    Let's compute the value:\n    $(0.98)^2 = 0.9604$.\n    $(0.98)^4 = (0.9604)^2 = 0.92236816$.\n    $P(\\text{identical}) = \\frac{0.92236816}{4} = 0.23059204$.\n\n    The problem requires the answer to be rounded to four significant figures. The first four significant figures are $2$, $3$, $0$, $5$. The fifth significant figure is $9$, which is greater than or equal to $5$, so we round up the last significant digit.\n    $0.23059204 \\approx 0.2306$.",
            "answer": "$$\n\\boxed{0.2306}\n$$"
        },
        {
            "introduction": "In the clinical laboratory, accurately determining an individual's HLA type is critical for transplantation and disease association studies. This exercise places you in the role of a clinical geneticist tasked with interpreting results from two different generations of technology: traditional serologic typing and modern molecular sequencing. By analyzing the apparent discrepancies between the two reports, you will uncover the limitations of older methods and appreciate why high-resolution molecular data is now the gold standard in histocompatibility testing .",
            "id": "5055675",
            "problem": "A laboratory evaluates an organ transplant candidate by two independent assays of Human Leukocyte Antigen (HLA) genes in the Major Histocompatibility Complex (MHC). The first is serologic typing using complement-dependent cytotoxicity (CDC), which detects cell-surface protein epitopes with antigen-specific antisera. The second is molecular typing by polymerase chain reaction (PCR) sequence-based typing (SBT), which reads coding-region deoxyribonucleic acid (DNA) sequences to infer alleles.\n\nUse the following foundational facts:\n- By the Central Dogma of Molecular Biology, DNA is transcribed to ribonucleic acid (RNA) and translated to protein, and cell-surface expression of a protein requires a functional open reading frame.\n- Classical class I HLA loci (HLA-A, HLA-B, HLA-C) and class II HLA loci (for example, HLA-DRB1, HLA-DQB1) are codominantly expressed, so in the absence of loss-of-function alleles, both parental alleles are present on the cell surface.\n- Serologic typing detects shared epitopes (antigenic specificities) on proteins; different alleles that encode identical or highly similar epitope structures can be indistinguishable by serology. Molecular typing distinguishes alleles by their DNA sequence, including synonymous and non-expressed (null) variants.\n\nThe patient’s results are:\n- Serologic typing (CDC):\n  - HLA-A: A2\n  - HLA-B: B7, B62\n  - HLA-C: Cw6\n  - HLA-DR: DR4, DR53\n  - HLA-DQ: DQ8\n- Molecular typing (PCR SBT):\n  - HLA-A: $\\mathrm{A}^*02:01$, $\\mathrm{A}^*02:09$\n  - HLA-B: $\\mathrm{B}^*07:02$, $\\mathrm{B}^*15:01$\n  - HLA-C: $\\mathrm{C}^*06:02$, $\\mathrm{C}^*07:02\\mathrm{N}$\n  - HLA-DRB1: $\\mathrm{DRB1}^*04:01$; HLA-DRB4: $\\mathrm{DRB4}^*01:03$\n  - HLA-DQB1: $\\mathrm{DQB1}^*03:02$\n\nWhich one of the following interpretations most accurately explains the observed pattern and highlights a key limitation of serologic typing relative to molecular typing?\n\nA. The presence of an HLA-C null allele led to apparent serologic homozygosity at HLA-C, whereas molecular typing detected the null allele, and two distinct HLA-A alleles within the A2 serogroup are indistinguishable by serology.\n\nB. Serology is inherently higher resolution than molecular typing for HLA-B and correctly identified $\\mathrm{B}^*07:02$ versus $\\mathrm{B}^*15:01$, which molecular typing missed.\n\nC. The discrepancy at HLA-A suggests a sequencing artifact; serology is the gold standard for distinguishing $\\mathrm{A}^*02:01$ from $\\mathrm{A}^*02:09$.\n\nD. The presence of DR53 by serology indicates a novel HLA-DRB1 allele not detectable by molecular typing.\n\nE. Molecular typing cannot detect expression differences; only serology can identify null alleles.",
            "solution": "The user has requested a critical validation of the problem statement, followed by a detailed solution and evaluation of the provided options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\nThe problem provides the following information:\n\n-   **Assay 1 (Serologic Typing - CDC):** Detects cell-surface protein epitopes using antigen-specific antisera.\n-   **Assay 2 (Molecular Typing - PCR SBT):** Reads coding-region deoxyribonucleic acid (DNA) sequences to infer alleles.\n-   **Foundational Fact 1 (Central Dogma):** DNA is transcribed to ribonucleic acid (RNA) and translated to protein. Cell-surface expression requires a functional open reading frame.\n-   **Foundational Fact 2 (Codominant Expression):** Classical class I (HLA-A, HLA-B, HLA-C) and class II (e.g., HLA-DRB1, HLA-DQB1) loci are codominantly expressed. In the absence of loss-of-function alleles, both parental alleles are expressed.\n-   **Foundational Fact 3 (Method Comparison):** Serology detects shared epitopes; different alleles may be indistinguishable. Molecular typing distinguishes alleles by DNA sequence, including synonymous and non-expressed (null) variants.\n-   **Patient Results (Serologic):**\n    -   HLA-A: A2\n    -   HLA-B: B7, B62\n    -   HLA-C: Cw6\n    -   HLA-DR: DR4, DR53\n    -   HLA-DQ: DQ8\n-   **Patient Results (Molecular):**\n    -   HLA-A: $\\mathrm{A}^*02:01$, $\\mathrm{A}^*02:09$\n    -   HLA-B: $\\mathrm{B}^*07:02$, $\\mathrm{B}^*15:01$\n    -   HLA-C: $\\mathrm{C}^*06:02$, $\\mathrm{C}^*07:02\\mathrm{N}$\n    -   HLA-DRB1: $\\mathrm{DRB1}^*04:01$; HLA-DRB4: $\\mathrm{DRB4}^*01:03$\n    -   HLA-DQB1: $\\mathrm{DQB1}^*03:02$\n-   **Question:** Which interpretation most accurately explains the observed pattern and highlights a key limitation of serologic typing relative to molecular typing?\n\n**Step 2: Validate Using Extracted Givens**\n\n-   **Scientifically Grounded:** The problem is based on fundamental principles of medical genetics and immunology, specifically the HLA system. The description of serologic and molecular typing methods is accurate. The concept of codominant expression, null alleles (indicated by the 'N' suffix in standard nomenclature), serologic groups versus specific alleles, and the genetic organization of the HLA-DR region (including loci like DRB1 and DRB4) are all established scientific facts.\n-   **Well-Posed:** The problem presents two sets of experimental data and asks for the best interpretation based on provided principles. The discrepancies between the two datasets are the core of the problem and are explainable, leading to a unique, correct interpretation.\n-   **Objective:** The problem is phrased in precise, objective, technical language. The data are presented without bias.\n-   **Completeness and Consistency:** The problem provides all necessary information to resolve the apparent discrepancies. The foundational facts serve as the rules for interpretation. The data are internally consistent with known principles of HLA genetics (e.g., the correspondence between serotype B62 and allele group B15, the existence of the $\\mathrm{A}^*02$ serogroup containing multiple alleles, and the DR4-DR53 association via the DRB1 and DRB4 loci).\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, and provides a clear basis for deriving a solution. The solution process may now proceed.\n\n### Derivation and Option Analysis\n\nThe task is to reconcile the serologic and molecular typing results, focusing on discrepancies that reveal the limitations of serology. We will analyze the results locus by locus.\n\n**1. Locus-by-Locus Analysis**\n\n-   **HLA-A:** Serology reports A2, suggesting homozygosity. Molecular typing reveals heterozygosity for two distinct alleles, $\\mathrm{A}^*02:01$ and $\\mathrm{A}^*02:09$. Both of these alleles encode proteins that carry the A2 epitope. This demonstrates a key limitation of serology: its resolution is insufficient to distinguish between different alleles that express the same or very similar surface antigens. This is a case of \"antigen splitting\" where molecular typing provides higher resolution.\n\n-   **HLA-B:** Serology reports two antigens, B7 and B62. Molecular typing reports two alleles, $\\mathrm{B}^*07:02$ and $\\mathrm{B}^*15:01$. The allele $\\mathrm{B}^*07:02$ encodes the B7 antigen. The allele $\\mathrm{B}^*15:01$ encodes the B62 antigen (B62 is a serologic \"split\" of the broader B15 antigen group). The results are concordant.\n\n-   **HLA-C:** Serology reports only Cw6, suggesting homozygosity. Molecular typing, however, identifies two different alleles: $\\mathrm{C}^*06:02$ and $\\mathrm{C}^*07:02\\mathrm{N}$.\n    -   $\\mathrm{C}^*06:02$ codes for the Cw6 protein, which is detected by serology.\n    -   $\\mathrm{C}^*07:02\\mathrm{N}$ is a *null allele*, indicated by the 'N' suffix. As stated in the foundational facts, a functional protein is not produced from this allele. Since serology detects cell-surface proteins, it cannot detect the product of a null allele.\n    -   This leads to \"apparent homozygosity\" in the serologic result. This is a critical limitation of serology: it cannot detect alleles that are not expressed on the cell surface.\n\n-   **HLA-DR:** Serology reports DR4 and DR53. Molecular typing reports $\\mathrm{DRB1}^*04:01$ and $\\mathrm{DRB4}^*01:03$. The DR4 specificity is encoded by the $\\mathrm{DRB1}^*04:01$ allele at the DRB1 locus. The DR53 specificity is encoded by the $\\mathrm{DRB4}^*01:03$ allele, which is at a separate locus, DRB4, that is frequently inherited along with certain DRB1 alleles like DR4. The results are concordant and illustrate the complex genetics of the Class II region, which molecular typing clarifies. The single DRB1 allele reported may indicate homozygosity or a partial typing result; however, the provided data are consistent.\n\n-   **HLA-DQ:** Serology reports DQ8. Molecular typing reports $\\mathrm{DQB1}^*03:02$. The $\\mathrm{DQB1}^*03:02$ allele encodes a protein with the DQ8 specificity. The results are concordant.\n\n**2. Synthesis and Evaluation of Options**\n\nThe analysis reveals two major discrepancies that highlight the limitations of serology:\n-   At HLA-A, serology has lower resolution than molecular typing.\n-   At HLA-C, serology fails to detect a null allele, giving a misleading result of homozygosity.\n\nWe now evaluate each option against this understanding.\n\n**A. The presence of an HLA-C null allele led to apparent serologic homozygosity at HLA-C, whereas molecular typing detected the null allele, and two distinct HLA-A alleles within the A2 serogroup are indistinguishable by serology.**\n-   **Justification:** This statement precisely and correctly describes the two key findings from our analysis. It identifies the \"apparent serologic homozygosity\" at HLA-C caused by the null allele $\\mathrm{C}^*07:02\\mathrm{N}$, which was correctly identified by molecular typing. It also correctly identifies the situation at HLA-A, where serology could not distinguish between two different alleles ($\\mathrm{A}^*02:01$ and $\\mathrm{A}^*02:09$) within the same serogroup (A2). This option perfectly captures the pattern and highlights fundamental limitations of serology.\n-   **Verdict:** **Correct**.\n\n**B. Serology is inherently higher resolution than molecular typing for HLA-B and correctly identified $\\mathrm{B}^*07:02$ versus $\\mathrm{B}^*15:01$, which molecular typing missed.**\n-   **Justification:** This statement is factually incorrect. First, molecular typing is inherently of higher resolution than serology, as it analyzes the underlying DNA sequence. Second, molecular typing did *not* miss the distinction; it reported $\\mathrm{B}^*07:02$ and $\\mathrm{B}^*15:01$, which correspond perfectly to the serotypes B7 and B62. The premise is false.\n-   **Verdict:** **Incorrect**.\n\n**C. The discrepancy at HLA-A suggests a sequencing artifact; serology is the gold standard for distinguishing $\\mathrm{A}^*02:01$ from $\\mathrm{A}^*02:09$.**\n-   **Justification:** This statement reverses the roles of the technologies. The discrepancy at HLA-A is a well-known feature of the A2 serogroup, not an artifact. Serology is fundamentally incapable of distinguishing alleles like $\\mathrm{A}^*02:01$ and $\\mathrm{A}^*02:09$ because they encode highly similar protein epitopes. DNA sequencing (molecular typing) is the definitive method—the \"gold standard\"—for making such a distinction.\n-   **Verdict:** **Incorrect**.\n\n**D. The presence of DR53 by serology indicates a novel HLA-DRB1 allele not detectable by molecular typing.**\n-   **Justification:** This interpretation is incorrect. DR53 is a well-known serologic specificity that is not encoded by the DRB1 locus. It is encoded by the DRB4 locus. The molecular typing result, $\\mathrm{DRB4}^*01:03$, is the specific allele that codes for the DR53 antigen. Therefore, molecular typing *did* detect the genetic basis for the DR53 serotype; it is not a novel or missed allele.\n-   **Verdict:** **Incorrect**.\n\n**E. Molecular typing cannot detect expression differences; only serology can identify null alleles.**\n-   **Justification:** This statement is the exact opposite of reality. Molecular typing identifies null alleles by finding mutations in the DNA sequence (e.g., premature stop codons, frameshifts) that are known to prevent protein expression; the 'N' suffix is a direct result of this molecular identification. Conversely, serology *cannot* identify null alleles because it looks for the protein product, which is absent. The absence of an expected antigen is merely suggestive, not definitive, evidence for a null allele from a serologic perspective.\n-   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "The Major Histocompatibility Complex is renowned for its role in presenting antigens to T cells, but its functions are far more diverse. This practice challenges you to think like a research scientist by piecing together experimental clues—from transcriptional regulation to protein interactions and effects on immune cells—to classify a newly discovered MHC gene. This exercise will deepen your understanding of nonclassical MHC molecules and their critical role as stress-inducible ligands that activate the innate immune system .",
            "id": "5055649",
            "problem": "A laboratory is characterizing a newly cloned Human Leukocyte Antigen (HLA) class I–like gene, provisionally named gene X. The gene maps to chromosome $6$p$21.3$ within the Major Histocompatibility Complex (MHC) class I region, between the canonical HLA class I loci. The team collects the following observations:\n\n1. Basal transcripts of gene X are low in most primary tissues, but increase more than $10$-fold after heat shock or ultraviolet-induced DNA damage. Interferon-$\\gamma$ (IFN-$\\gamma$) treatment produces minimal change in transcript abundance compared with classical HLA class I genes.\n\n2. The encoded surface protein is detectable in a conformation that does not co-immunoprecipitate with $\\beta_2$-microglobulin, and structural modeling predicts only a shallow groove inconsistent with high-affinity peptide loading.\n\n3. When gene X is overexpressed in a human tumor cell line, Natural Killer (NK) cell cytotoxicity increases; cytotoxicity is blocked by a monoclonal antibody to NKG$2$D, but not by an antibody to CD$94$.\n\n4. Population sequencing across unrelated donors reveals moderate polymorphism at nonsynonymous sites: fewer alleles than HLA-B, but more than HLA-E.\n\nUsing only first principles from the Central Dogma of molecular biology (DNA $\\rightarrow$ RNA $\\rightarrow$ protein), the immunologic principle that NK cells integrate activating and inhibitory signals based on self-recognition and stress-induced cues, and canonical features of MHC genetics (e.g., polymorphism and gene clustering at chromosome $6$p$21.3$), which option best identifies gene X and its immunological role?\n\nA. HLA-E; a nonclassical class I molecule that presents leader peptide–derived ligands to CD$94$/NKG$2$A, delivering inhibitory signals to NK cells.\n\nB. HLA-G; a nonclassical class I molecule mediating maternal–fetal tolerance via Leukocyte Immunoglobulin-like Receptor B$1$ (LILRB$1$), with expression largely restricted to trophoblasts and not acutely responsive to cellular stress.\n\nC. MIC-A/MIC-B family; stress-inducible class I–like molecules within the MHC that act as ligands for NKG$2$D, enhancing NK cell–mediated cytotoxicity independently of $\\beta_2$-microglobulin and high-affinity peptide presentation.\n\nD. UL16-binding proteins (ULBPs); stress-inducible glycosylphosphatidylinositol-anchored ligands encoded outside the MHC that bind CD$94$/NKG$2$ receptors and inhibit NK cells.",
            "solution": "We are asked to deduce the best identity and role of gene X from fundamental principles and well-tested facts:\n\n- By the Central Dogma (DNA $\\rightarrow$ RNA $\\rightarrow$ protein), stimulus-dependent increases in mRNA (e.g., after heat shock or DNA damage) imply transcriptional upregulation via stress-responsive pathways, a hallmark of stress-inducible ligands rather than constitutively expressed antigen-presenting molecules. In contrast, classical HLA class I genes are strongly upregulated by interferon-$\\gamma$ (IFN-$\\gamma$) through Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling and interferon-stimulated response elements; minimal response of gene X to IFN-$\\gamma$ points away from classical antigen-presenting function.\n\n- Natural Killer (NK) cells integrate inhibitory and activating signals. A canonical inhibitory pathway relies on recognition of “self” Major Histocompatibility Complex (MHC) class I molecules by inhibitory receptors (e.g., CD$94$/NKG$2$A sensing HLA-E or Leukocyte Immunoglobulin-like Receptors sensing HLA-G). Activating signals can be triggered by stress-induced ligands such as MHC class I polypeptide–related sequence A/B (MIC-A/MIC-B) and UL16-binding proteins (ULBPs) engaging NKG$2$D. Blocking of cytotoxicity by anti-NKG$2$D but not by anti-CD$94$ indicates that the relevant ligand is for NKG$2$D and not for CD$94$-containing receptors.\n\n- Structural association with $\\beta_2$-microglobulin is a defining feature of many peptide-presenting class I molecules (both classical and several nonclassical), stabilizing the peptide-binding groove. The lack of $\\beta_2$-microglobulin association and prediction of a shallow groove suggest a class I–like molecule that is not a canonical peptide-presenting platform.\n\n- Genomic context at chromosome $6$p$21.3$ (within the MHC) supports an MHC-encoded ligand (e.g., HLA or MIC), whereas ULBPs, although stress-inducible and NKG$2$D-binding, are generally encoded outside the core MHC region.\n\n- Patterns of polymorphism reflect evolutionary pressures: extremely high polymorphism in classical HLA-A/B/C due to pathogen-driven balancing selection, low polymorphism in nonclassical HLA-E/F/G due to constrained specialized functions, and intermediate-to-moderate polymorphism in some stress ligands (e.g., MICA) reflecting population-level variation under distinct selection regimes. The observation “fewer alleles than HLA-B, but more than HLA-E” aligns with MICA/MICB.\n\nApplying these principles to each option:\n\nOption A: HLA-E is a nonclassical class I molecule that binds leader peptides from other HLA class I molecules and presents them with $\\beta_2$-microglobulin to CD$94$/NKG$2$A (inhibitory) or CD$94$/NKG$2$C (activating) receptors. HLA-E is generally upregulated by IFN-$\\gamma$ through increased supply of peptides and heavy chain expression and critically depends on CD$94$ interactions. The data show minimal IFN-$\\gamma$ response, no $\\beta_2$-microglobulin association, and no effect of anti-CD$94$, which contradicts the HLA-E identity. Verdict — Incorrect.\n\nOption B: HLA-G is a nonclassical class I molecule with restricted expression (notably extravillous trophoblast), associates with $\\beta_2$-microglobulin and can present limited peptides and interact with inhibitory receptors such as LILRB$1$/LILRB$2$, contributing to tolerance. Acute stress-induced upregulation after heat shock/UV and NKG$2$D-dependent NK activation are not characteristic of HLA-G. The lack of $\\beta_2$-microglobulin association further argues against HLA-G. Verdict — Incorrect.\n\nOption C: MIC-A/MIC-B are MHC-encoded, class I–like molecules within the MHC class I region that are stress-inducible (upregulated by heat shock and DNA damage pathways), typically do not associate with $\\beta_2$-microglobulin, do not bind peptides in a classical groove, and serve as ligands for NKG$2$D, delivering activating signals to NK cells. They exhibit polymorphism intermediate between classical and nonclassical HLA molecules. The genomic location (within the MHC), stress-responsive transcription, absence of $\\beta_2$-microglobulin, NKG$2$D dependence, and polymorphism profile all align with MIC-A/MIC-B. Verdict — Correct.\n\nOption D: UL16-binding proteins (ULBPs) are stress-inducible NKG$2$D ligands; many are glycosylphosphatidylinositol-anchored and encoded outside the core MHC region. However, they do not bind CD$94$/NKG$2$ receptors, nor do they deliver inhibitory signals; rather, they activate NK cells via NKG$2$D. The option incorrectly assigns CD$94$/NKG$2$ binding and inhibition, and the mapping of gene X within the MHC does not match typical ULBP loci. Verdict — Incorrect.\n\nTherefore, the best identification is MIC-A/MIC-B as stress-inducible NKG$2$D ligands encoded within the MHC that activate NK cells independently of $\\beta_2$-microglobulin and classical peptide presentation.",
            "answer": "$$\\boxed{C}$$"
        }
    ]
}